Personalising Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer: Protocols for the International Phase III FOxTROT2 and FOxTROT3 Randomised-Controlled Trials.
James R PlattChristopher J M WilliamsZoe CraigDavid A CairnsJames C GlasbeyDion MortonJenny SeligmannPublished in: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2023)
FOxTROT2 and FOxTROT3 will establish the FOxTROT platform, a key part of our long-term strategy to develop neoadjuvant treatments for CC. FOxTROT2 will investigate NAC in a population under-represented in FOxTROT1 and wider research. FOxTROT3 will assess whether it is possible to induce greater early tumour responses and whether this translates to superior long-term outcomes. Looking ahead, the FOxTROT platform will facilitate further trial comparisons and extensive translational research to optimise the use of NAC in CC.